Collegium Pharmaceutical, Inc. - Common Stock (NQ:COLL)

21.91 +0.03 (+0.11%)

Delayed Quote Updated: 1:40 PM EDT, Oct 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Collegium Pharmaceutical, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Collegium Pharmaceutical Inc (NASDAQ:COLL) Beats Q3 2025 Estimates and Raises Full-Year Guidance ↗

November 06, 2025

Collegium Pharmaceutical (COLL) beat Q3 2025 earnings estimates and raised its full-year guidance, driven by strong performance in its pain and ADHD portfolios.

Via Chartmill

Collegium Pharmaceutical (NASDAQ:COLL) Delivers Impressive Q3, Stock Jumps 12.1%

November 06, 2025

Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) beat Wall Street’s revenue expectations in Q3 CY2025, with sales up 31.4% year on year to $209.4 million. The company’s full-year revenue...

Via StockStory

Collegium Reports Third Quarter 2025 Financial Results; Raises 2025 Guidance

November 06, 2025

From Collegium Pharmaceutical, Inc.

Via GlobeNewswire

Earnings Scheduled For November 6, 2025 ↗

November 06, 2025

Via Benzinga

Earnings To Watch: Collegium Pharmaceutical (COLL) Reports Q3 Results Tomorrow

November 04, 2025

Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) will be announcing earnings results this Thursday before market open. Here’s what investors should know.

Via StockStory

Earnings Scheduled For August 7, 2025 ↗

August 07, 2025

Via Benzinga

3 Stocks Under $50 That Fall Short

October 31, 2025

The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to...

Via StockStory

Topics Artificial Intelligence

Paris Hilton Collaborates with Collegium Pharmaceutical to Share Her Personal ADHD Journey and Experience with Treatment

October 29, 2025

From Collegium Pharmaceutical, Inc.

Via GlobeNewswire

Collegium to Report Third Quarter 2025 Financial Results on November 6, 2025

October 23, 2025

From Collegium Pharmaceutical, Inc.

Via GlobeNewswire

Collegium Pharmaceutical (COLL): Buy, Sell, or Hold Post Q2 Earnings?

October 23, 2025

Collegium Pharmaceutical has had an impressive run over the past six months as its shares have beaten the S&P 500 by 10%. The stock now trades at $35.02, marking a 34.7% gain. This was partly thanks to...

Via StockStory

Topics Stocks Supply Chain

Collegium Announces Poster Presentations at the American Academy of Child & Adolescent Psychiatry and Neuroscience Education Institute Conferences

October 22, 2025

From Collegium Pharmaceutical, Inc.

Via GlobeNewswire

Collegium to Celebrate 10-Year Anniversary with Nasdaq Opening Bell Ringing

October 13, 2025

– Collegium to Ring Nasdaq Opening Bell on October 14, 2025 –

From Collegium Pharmaceutical, Inc.

Via GlobeNewswire

UnitedHealth, Brookdale, Collegium Pharmaceutical, QuidelOrtho, and Biogen Shares Are Falling, What You Need To Know

October 10, 2025

A number of stocks fell in the afternoon session after worries over worsening trade relations with China were triggered by critical comments from President Donald Trump.

Via StockStory

Topics Economy Government World Trade

1 Russell 2000 Stock to Research Further and 2 We Avoid

September 26, 2025

The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size also means these businesses often lack the...

Via StockStory

Branded Pharmaceuticals Stocks Q2 Highlights: Collegium Pharmaceutical (NASDAQ:COLL)

September 24, 2025

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Collegium Pharmaceutical...

Via StockStory

Topics Artificial Intelligence Intellectual Property

1 Safe-and-Steady Stock to Keep an Eye On and 2 Facing Headwinds

September 12, 2025

A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.

Via StockStory

Collegium to Participate in Upcoming Investor Conferences

August 28, 2025

From Collegium Pharmaceutical, Inc.

Via GlobeNewswire

Collegium to Present Nine Real-World Data Posters at PAINWeek 2025 Annual Meeting

August 25, 2025

From Collegium Pharmaceutical, Inc.

Via GlobeNewswire

1 Stock Under $50 Worth Investigating and 2 We Ignore

August 13, 2025

Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline prices don’t guarantee quality, and...

Via StockStory

3 Profitable Stocks We Think Twice About

August 12, 2025

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.

Via StockStory

COLL Q2 Deep Dive: Jornay Expansion Drives Revenue Guidance Increase, Margins Face Investment Pressure

August 12, 2025

Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) reported Q2 CY2025 results topping the market’s revenue expectations, with sales up 29.4% year on year to $188 million. The company’s...

Via StockStory

Collegium Pharmaceutical (NASDAQ:COLL) Exceeds Q2 Expectations, Stock Jumps 10.2%

August 07, 2025

Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) reported Q2 CY2025 results beating Wall Street’s revenue expectations, with sales up 29.4% year on year to $188 million. The company’s...

Via StockStory

Collegium (COLL) Q2 Revenue Jumps 29% ↗

August 07, 2025

Via The Motley Fool

Topics Intellectual Property

Collegium Pharmaceutical Inc (NASDAQ:COLL) Reports Record Q2 2025 Earnings and Raises Full-Year Guidance ↗

August 07, 2025

Collegium Pharmaceutical (COLL) reports strong Q2 2025 earnings, beating estimates with $188M revenue (+29% YoY) and $1.68 EPS. Raised full-year guidance and new $150M buyback program signal growth...

Via Chartmill

Collegium Reports Second Quarter 2025 Financial Results; Raises 2025 Outlook

August 07, 2025

From Collegium Pharmaceutical, Inc.

Via GlobeNewswire

Collegium Pharmaceutical (COLL) Q2 Earnings: What To Expect

August 05, 2025

Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) will be reporting earnings this Thursday morning. Here’s what you need to know.

Via StockStory

Topics Government World Trade

1 Cash-Producing Stock to Own for Decades and 2 We Ignore

August 04, 2025

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak...

Via StockStory

Collegium to Report Second Quarter 2025 Financial Results on August 7, 2025

July 24, 2025

From Collegium Pharmaceutical, Inc.

Via GlobeNewswire

5 Hot Stocks With Summer Buybacks You Can Cash In On ↗

July 10, 2025

The five stocks on this list issued aggressive buyback authorizations in June or July and have the power to follow through with their plans.

Via MarketBeat

1 Safe-and-Steady Stock to Keep an Eye On and 2 to Be Wary Of

July 08, 2025

Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies.

Via StockStory

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.